Single-Dose Anti-CD138 Radioimmunotherapy: Bismuth-213 is More Efficient than Lutetium-177 for Treatment of Multiple Myeloma in a Preclinical Model
about
Multiple myeloma in the marrow: pathogenesis and treatments.Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle.Bifunctional aryliodonium salts for highly efficient radioiodination and astatination of antibodies.Comparison of Immuno-PET of CD138 and PET imaging with 64CuCl2 and 18F-FDG in a preclinical syngeneic model of multiple myeloma.
P2860
Single-Dose Anti-CD138 Radioimmunotherapy: Bismuth-213 is More Efficient than Lutetium-177 for Treatment of Multiple Myeloma in a Preclinical Model
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Single-Dose Anti-CD138 Radioim ...... Myeloma in a Preclinical Model
@ast
Single-Dose Anti-CD138 Radioim ...... Myeloma in a Preclinical Model
@en
type
label
Single-Dose Anti-CD138 Radioim ...... Myeloma in a Preclinical Model
@ast
Single-Dose Anti-CD138 Radioim ...... Myeloma in a Preclinical Model
@en
prefLabel
Single-Dose Anti-CD138 Radioim ...... Myeloma in a Preclinical Model
@ast
Single-Dose Anti-CD138 Radioim ...... Myeloma in a Preclinical Model
@en
P2093
P2860
P356
P1476
Single-Dose Anti-CD138 Radioim ...... Myeloma in a Preclinical Model
@en
P2093
Alfred Morgenstern
Catherine Maurel
Edith Bigot-Corbel
Frank Bruchertseifer
François Davodeau
Jacques Barbet
Ludovic Ferrer
Michel Chérel
Nolwenn Fichou
Sébastien Gouard
P2860
P356
10.3389/FMED.2015.00076
P577
2015-11-04T00:00:00Z